Can probiotic, prebiotic, and synbiotic supplementation modulate the gut-liver axis in type 2 diabetes? A narrative and systematic review of clinical trials.
clinical trial
dysbiosis
gut microbiome
liver function
nutraceutical
Journal
Frontiers in nutrition
ISSN: 2296-861X
Titre abrégé: Front Nutr
Pays: Switzerland
ID NLM: 101642264
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
09
2022
accepted:
16
11
2022
entrez:
19
12
2022
pubmed:
20
12
2022
medline:
20
12
2022
Statut:
epublish
Résumé
Type 2 diabetes, one of the most common noncommunicable diseases, is a metabolic disorder that results in failed homeostatic control in several body systems, including hepatic function. Due to the gut microbiome's potential role in diabetes' pathogenesis, prebiotics, probiotics, and synbiotics have been proposed as complimentary therapeutic approaches aimed at microbiota readjustment. A systematic review was conducted on PubMed, Scopus, Web of Science, Embase, and the Cochrane Library examining the effect of probiotics, prebiotics, and synbiotics on hepatic biomarkers in patients with diabetes. From 9,502 search hits, 10 studies met the inclusion criteria and were included in this review. A total of 816 participants (460 intervention and 356 control) were investigated for the effects of nine different hepatic biomarker measurements including aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total protein, bilirubin, liver steatosis, liver stiffness, fatty liver index, and gamma-glutamyl transferase levels. Of the 13 intervention groups analyzed from the 10 studies, 3 were prebiotic interventions, 3 were single species probiotic interventions, 3 were multi-species probiotic interventions, and 4 were synbiotic interventions. Nutraceuticals used in these trials included six genera of bacteria ( Although some studies showed insignificant changes in hepatic biomarkers, generally the results yielded a decrease in liver damage due to reduced oxidative stress, pro-inflammatory cytokines, gut dysbiosis, and insulin resistance which led to improvements in hepatic biomarker levels.
Sections du résumé
Background
UNASSIGNED
Type 2 diabetes, one of the most common noncommunicable diseases, is a metabolic disorder that results in failed homeostatic control in several body systems, including hepatic function. Due to the gut microbiome's potential role in diabetes' pathogenesis, prebiotics, probiotics, and synbiotics have been proposed as complimentary therapeutic approaches aimed at microbiota readjustment.
Methods
UNASSIGNED
A systematic review was conducted on PubMed, Scopus, Web of Science, Embase, and the Cochrane Library examining the effect of probiotics, prebiotics, and synbiotics on hepatic biomarkers in patients with diabetes.
Results
UNASSIGNED
From 9,502 search hits, 10 studies met the inclusion criteria and were included in this review. A total of 816 participants (460 intervention and 356 control) were investigated for the effects of nine different hepatic biomarker measurements including aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total protein, bilirubin, liver steatosis, liver stiffness, fatty liver index, and gamma-glutamyl transferase levels. Of the 13 intervention groups analyzed from the 10 studies, 3 were prebiotic interventions, 3 were single species probiotic interventions, 3 were multi-species probiotic interventions, and 4 were synbiotic interventions. Nutraceuticals used in these trials included six genera of bacteria (
Conclusion
UNASSIGNED
Although some studies showed insignificant changes in hepatic biomarkers, generally the results yielded a decrease in liver damage due to reduced oxidative stress, pro-inflammatory cytokines, gut dysbiosis, and insulin resistance which led to improvements in hepatic biomarker levels.
Identifiants
pubmed: 36532552
doi: 10.3389/fnut.2022.1052619
pmc: PMC9751375
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
1052619Informations de copyright
Copyright © 2022 Al-Najjar, Arabi, Paul and Chaari.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Nutr. 2016 Aug;35(4):819-25
pubmed: 26209256
BMC Physiol. 2008 Oct 10;8:19
pubmed: 18847460
Science. 2005 Jan 21;307(5708):384-7
pubmed: 15662004
Diabetol Metab Syndr. 2019 Feb 07;11:14
pubmed: 30774722
EMBO Mol Med. 2019 Feb;11(2):
pubmed: 30591521
Benef Microbes. 2017 Oct 13;8(5):705-716
pubmed: 28884590
Lancet. 1972 Mar 25;1(7752):685-7
pubmed: 4125186
Front Nutr. 2022 May 25;9:906243
pubmed: 35711547
Int J Prev Med. 2017 Jun 01;8:43
pubmed: 28656099
Arterioscler Thromb Vasc Biol. 1996 Feb;16(2):250-5
pubmed: 8620339
Int J Environ Res Public Health. 2022 Jan 21;19(3):
pubmed: 35162231
Pharmacol Res. 2022 Nov;185:106520
pubmed: 36272640
Foods. 2019 Mar 09;8(3):
pubmed: 30857316
Clin Nutr ESPEN. 2022 Jun;49:264-269
pubmed: 35623824
Liver Int. 2008 May;28(5):592-605
pubmed: 18433389
Nature. 2006 Dec 21;444(7122):1027-31
pubmed: 17183312
Am J Med. 2017 Jun;130(6S):S4-S17
pubmed: 28526182
Br J Nutr. 2022 Aug 28;128(4):625-635
pubmed: 34544511
Medicine (Baltimore). 2016 Feb;95(5):e2658
pubmed: 26844491
Trends Microbiol. 1996 Nov;4(11):430-5
pubmed: 8950812
Food Funct. 2019 Sep 1;10(9):5804-5815
pubmed: 31461095
Nat Clin Pract Endocrinol Metab. 2006 Jun;2(6):335-48
pubmed: 16932311
Diabetes. 2014 Aug;63(8):2613-6
pubmed: 25060893
J Epidemiol Glob Health. 2020 Mar;10(1):107-111
pubmed: 32175717
World J Gastroenterol. 2014 Dec 21;20(47):17737-45
pubmed: 25548472
Crit Rev Food Sci Nutr. 2020;60(4):670-683
pubmed: 30632770
BMC Complement Altern Med. 2015 Dec 12;15:433
pubmed: 26654906
Front Nutr. 2020 Sep 24;7:563605
pubmed: 33072796
Front Endocrinol (Lausanne). 2020 Jan 31;11:25
pubmed: 32082260
Microorganisms. 2022 Jan 26;10(2):
pubmed: 35208742
Biomedicines. 2020 Jan 07;8(1):
pubmed: 31936158
Benef Microbes. 2017 Aug 24;8(4):545-556
pubmed: 28701081
Annu Rev Nutr. 2002;22:283-307
pubmed: 12055347
Sultan Qaboos Univ Med J. 2016 May;16(2):e132-41
pubmed: 27226903
Nature. 2006 Dec 21;444(7122):1022-3
pubmed: 17183309
Sci Rep. 2017 Sep 21;7(1):12115
pubmed: 28935921
EXCLI J. 2016 Dec 15;15:817-828
pubmed: 28337112
Int J Mol Sci. 2019 Jan 21;20(2):
pubmed: 30669548
PLoS One. 2018 Mar 20;13(3):e0194127
pubmed: 29558518
J Chemother. 2009 Aug;21(4):371-7
pubmed: 19622453
Br J Nutr. 2010 Aug;104 Suppl 2:S1-63
pubmed: 20920376
Life Sci. 2022 Sep 15;305:120760
pubmed: 35787997
Diabetes Care. 2015 Jan;38(1):140-9
pubmed: 25538310
mSystems. 2021 Jun 29;6(3):e0038421
pubmed: 34128694
Cell. 2018 Mar 8;172(6):1198-1215
pubmed: 29522742
Nat Rev Gastroenterol Hepatol. 2020 Nov;17(11):687-701
pubmed: 32826966
BMC Endocr Disord. 2019 Oct 15;19(1):100
pubmed: 31615498
Postgrad Med J. 1980 Nov;56(661):767-72
pubmed: 7267479
Diabetol Metab Syndr. 2018 Jun 19;10:51
pubmed: 29946368
Iran J Basic Med Sci. 2019 Aug;22(8):956-962
pubmed: 31579453
Complement Ther Med. 2021 May;58:102699
pubmed: 33639251
Sci Rep. 2017 Jul 5;7(1):4649
pubmed: 28680048
Biology (Basel). 2021 Apr 13;10(4):
pubmed: 33924344
Adv Pharm Bull. 2018 Nov;8(4):565-574
pubmed: 30607329
J Am Coll Nutr. 2016 Aug;35(6):506-513
pubmed: 26430929
J Diabetes Metab Disord. 2019 Dec 23;19(1):53-60
pubmed: 32550156
Diabetes Res Clin Pract. 2022 Jan;183:109119
pubmed: 34879977
Trials. 2016 Jul 26;17(1):347
pubmed: 27456494
Am J Clin Nutr. 1979 Jan;32(1):149-57
pubmed: 367142
Front Cell Infect Microbiol. 2021 Jan 21;10:595759
pubmed: 33553004
Br J Nutr. 2002 May;87 Suppl 2:S139-43
pubmed: 12088510
Molecules. 2021 Oct 08;26(19):
pubmed: 34641619
Eur J Clin Nutr. 2007 Oct;61(10):1189-95
pubmed: 17268410
Biomed Pharmacother. 2021 Sep;141:111817
pubmed: 34126349
Arch Med Sci. 2018 Jan;14(1):81-87
pubmed: 29379536
J Basic Microbiol. 1999;39(1):3-9
pubmed: 10071861
Cell. 2010 Jun 25;141(7):1241-52
pubmed: 20603004
Prim Care Diabetes. 2016 Aug;10(4):265-71
pubmed: 26872721
Nutr Metab Cardiovasc Dis. 2005 Aug;15(4):316-28
pubmed: 16054557
Science. 1987 Feb 27;235(4792):1043-6
pubmed: 3029864
BMC Endocr Disord. 2018 Apr 12;18(1):21
pubmed: 29649996
Nutrients. 2019 Mar 15;11(3):
pubmed: 30875987
Endocrinol Metab (Seoul). 2013 Mar;28(1):26-32
pubmed: 24396647
Diabetes Obes Metab. 2017 Apr;19(4):579-589
pubmed: 28009106
Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14
pubmed: 24912386
Front Endocrinol (Lausanne). 2021 Apr 07;12:632335
pubmed: 33897618
J Res Med Sci. 2011 Feb;16(2):123-9
pubmed: 22091220